Understanding how to improve cancer treatment by targeting immune cells in head and neck cancers
Tackling Treg mediated resistance to radiation and anti-PDL1 in HNSCCs
This study is looking at how certain immune cells can help make radiation and immunotherapy work better for people with head and neck cancers, and it aims to find the best treatment combinations to boost the immune system and lower the chances of cancer coming back in the lymph nodes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-10998838 on NIH RePORTER |
What this research studies
This research investigates the role of specific immune cells, known as Tregs, in the effectiveness of radiation therapy and immunotherapy for head and neck cancers. The study aims to determine how different combinations of treatments can influence the immune response and reduce the risk of cancer recurrence in lymph nodes. By analyzing preclinical models and patient data, the researchers hope to identify strategies that enhance the immune system's ability to fight cancer while minimizing the negative effects of radiation. Patients may be involved in trials that explore these innovative treatment combinations.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with head and neck cancers who are undergoing treatment involving radiation and immunotherapy.
Not a fit: Patients with head and neck cancers who are not receiving radiation therapy or immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment strategies for patients with head and neck cancers, potentially reducing recurrence rates and improving overall outcomes.
How similar studies have performed: Previous research has shown promising results in enhancing cancer treatment outcomes through targeted immunotherapy approaches, indicating that this line of investigation has potential for success.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Karam, Sana D — University of Colorado Denver
- Study coordinator: Karam, Sana D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.